OTTAWA, July 26, 2013 /CNW/ - The Ontario Superior Court has certified a class action for Canadians who took Champix between April 2, 2007 and May 31, 2010 and allegedly suffered certain reactions. The lawsuit seeks compensation and alleges that, between April 2, 2007 and May 31, 2010, Pfizer Canada Inc. failed to adequately warn of the risk of certain psychiatric adverse events allegedly related to Champix. Pfizer Canada Inc. denies the allegations, which have not been established, and is defending the lawsuit.
The class action lawsuit affects all Canadians who took Champix during the period from April 2, 2007 to May 31, 2010 and who, while taking or after taking Champix to help quit smoking, experienced any of the psychiatric adverse events or symptoms listed below:
- thoughts about suicide or dying
- attempts to commit suicide
- new or worse depression, anxiety or panic attacks
- feeling very agitated or restless
- acting aggressive, being angry or violent
- acting on dangerous impulses
- an extreme increase in activity and talking (mania)
- abnormal thoughts or sensations
- seeing or hearing things that are not there (hallucinations)
- feeling people are against you (paranoia)
- feeling confused
- other unusual changes in behaviours
If any Canadian fits the above description, this person is a member of the "Class".
Any individual that is a relative of a member of the Class who is entitled to make claims under any of the Dependants Statutes in Canada as a result of the death or personal injury of their relative that took Champix, is a member of the "Family Class".
Class members and Family Class members do not need to do anything at this stage to participate - they are automatically included in the class action but are encouraged however to contact Class Counsel for more information, and to discuss the steps necessary for preserving medical records needed for any claims that may be advanced on their behalf.
Class members or Family Class members who do not exclude themselves by September 20, 2013 will be included in this lawsuit and will be forever bound by the Court's judgment on the common issues, whether favourable or not. The only option that allows Class members to ever be part of any other lawsuit against Pfizer regarding the legal claims in this case, is by opting out by no later than September 20, 2013.
Individuals who do not want to be part of this lawsuit must notify Class Counsel in writing, by no later than September 20, 2013, providing their name and address and indicating a clear desire to not be part of this lawsuit.
Class members who consider it desirable or necessary to seek the advice or representation of their own lawyers may do so at their own expense.
The following law firms represent Class members:
- For residents of Ontario, British Columbia, Alberta, Nova Scotia, New Brunswick, Newfoundland and Labrador, Manitoba, Saskatchewan, Yukon, North West Territories, Nunavut, and residents outside of Canada: McPHADDEN SAMAC TUOVI LLP (416) 601-1020, KLEIN LYONS LLP (604) 874-7171, DOCKEN KLYM (403) 269-3612.
- For residents of Québec: LAUZON BÉLANGER LÉSPERANCE (514) 844-4646.
For more information:
This press release is just a summary of the certification. The Court approved Legal Notice is available by visiting www.champixclassactioninfo.ca.
Do not contact the Court about this press release.
SOURCE: Bruneau Group Inc.
For further information:
For residents of Ontario, British Columbia, Alberta, Nova Scotia, New Brunswick, Newfoundland and Labrador, Manitoba, Saskatchewan, Yukon, North West Territories, Nunavut, and residents outside of Canada: McPHADDEN SAMAC TUOVI LLP (416) 601-1020, KLEIN LYONS LLP (604) 874-7171, DOCKEN KLYM (403) 269-3612.
For residents of Québec: LAUZON BÉLANGER LÉSPERANCE (514) 844-4646.